REPLIMUNE GROUP INC. - COMMON STOCK

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Nov 2024 13:01:00 By Nasdaq GlobeNewswire

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

30 Oct 2024 06:15:09 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Oct 2024 13:01:00 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

01 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

15 Sep 2024 06:45:00 By Nasdaq GlobeNewswire

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024

09 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Stockholders Vote to Elect Madhavan Balachandran to Board of Directors

05 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024

22 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

13 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

08 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

30 Jul 2024 13:01:00 By Nasdaq GlobeNewswire

Replimune Announces $100 Million Private Placement Financing

13 Jun 2024 05:30:00 By Nasdaq GlobeNewswire

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

07 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

06 Jun 2024 04:00:00 By Nasdaq GlobeNewswire

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

03 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 May 2024 14:00:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

16 May 2024 05:00:00 By Nasdaq GlobeNewswire

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

07 Apr 2024 14:00:00 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2024 05:00:00 By Nasdaq GlobeNewswire

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

26 Mar 2024 04:30:00 By Nasdaq GlobeNewswire